Kasim-Karakas S E, Herrmann R, Almario R
Division of Clinical Nutrition, University of California at Davis, Sacramento 95817, USA.
Metabolism. 1995 Sep;44(9):1223-30. doi: 10.1016/0026-0495(95)90020-9.
Very-low-density lipoproteins (VLDLs) are the major carriers of fasting plasma triglyceride (TG). TG-enriched VLDLs become cholesterol (C)-enriched low-density lipoproteins (LDLs) through hydrolysis facilitated by lipoprotein lipase (LPL). Omega-3 fatty acid (n-3 FA) supplementation may increase LDL-C while decreasing plasma TG in hypertriglyceridemic patients. It has been proposed that n-3 FAs increase LDL-C by promoting production of TG-poor VLDL and accelerating conversion of VLDL to LDL. To study the effects of n-3 FA supplementation on in vivo lipolysis of VLDL directly, we treated 11 hypertriglyceridemic subjects with n-3 FA (3.3 g/d). Each participant was studied three times: at baseline, after a 1-month period of run-in olive oil placebo, and after 1 more month of n-3 FA supplementation. Lipolysis was induced by intravenous infusion of heparin for 2 hours. Plasma samples were obtained every 30 minutes for determination of lipids and apoproteins (apos), separation of individual lipoproteins by fast protein liquid chromatography (FPLC), and measurement of LPL and hepatic TG lipase (HTGL) levels. n-3 FA supplementation decreased fasting plasma TG (2.51 +/- 0.23 v 3.97 +/- 0.46 mmol/L), VLDL-TG (1.08 +/- 0.18 v 2.35 +/- 0.35 mmol/L), and VLDL-C (0.39 +/- 0.05 v 0.72 +/- 0.13 mmol/L) while increasing LDL-C (3.59 +/- 0.21 v 3.00 +/- 0.23 mmol/L) and plasma apo B (3.31 +/- 0.19 v 2.90 +/- 0.17 mmol/L). The absolute rate of TG lipolysis correlated with fasting TG (r = .74, P < .005) and was lower after n-3 FA supplementation (0.11 +/- 0.01 mmol/mL/min) as compared with placebo (0.19 +/- 0.01, P < .01), whereas percent decreases from baseline TG levels were similar at entry onto the study (57.4% +/- 2.5%), after placebo (58.8% +/- 2.7%), and after n-3 FA (52% +/- 3.6%).(ABSTRACT TRUNCATED AT 250 WORDS)
极低密度脂蛋白(VLDL)是空腹血浆甘油三酯(TG)的主要载体。富含TG的VLDL通过脂蛋白脂肪酶(LPL)促进的水解作用转变为富含胆固醇(C)的低密度脂蛋白(LDL)。补充ω-3脂肪酸(n-3 FA)可能会使高甘油三酯血症患者的低密度脂蛋白胆固醇(LDL-C)升高,同时降低血浆TG水平。有人提出,n-3 FA通过促进生成低TG的VLDL以及加速VLDL向LDL的转化来增加LDL-C。为了直接研究补充n-3 FA对体内VLDL脂解作用的影响,我们对11名高甘油三酯血症患者给予n-3 FA(3.3 g/天)治疗。每位参与者接受三次研究:基线时、在1个月的橄榄油安慰剂导入期后以及在再补充1个月n-3 FA后。通过静脉输注肝素2小时诱导脂解。每30分钟采集血浆样本,用于测定脂质和载脂蛋白(apo),通过快速蛋白质液相色谱(FPLC)分离单个脂蛋白,并测量LPL和肝甘油三酯脂肪酶(HTGL)水平。补充n-3 FA可降低空腹血浆TG(2.51±0.23对3.97±0.46 mmol/L)、VLDL-TG(1.08±0.18对2.35±0.35 mmol/L)和VLDL-C(0.39±0.05对0.72±0.13 mmol/L),同时增加LDL-C(3.59±0.21对3.00±0.23 mmol/L)和血浆载脂蛋白B(3.31±0.19对2.90±0.17 mmol/L)。TG脂解的绝对速率与空腹TG相关(r = 0.74,P < 0.005),与安慰剂相比,补充n-3 FA后较低(0.11±0.01 mmol/mL/分钟对0.19±0.01,P < 0.01),而从基线TG水平下降的百分比在进入研究时(57.4%±2.5%)、安慰剂后(58.8%±2.7%)和n-3 FA后(52%±3.6%)相似。(摘要截短至250字)